Clinical Trials Logo

Cervical Adenocarcinoma clinical trials

View clinical trials related to Cervical Adenocarcinoma.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT02921269 Completed - Clinical trials for Cervical Adenocarcinoma

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

Start date: March 10, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with cervical cancer that has come back, remains despite treatment, or has spread to other places in the body. Monoclonal antibodies, such as atezolizumab and bevacizumab, may shrink tumor cell and interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02880007 Completed - Clinical trials for Cervical Adenocarcinoma

Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical Cancer

TRIDICOL
Start date: June 6, 2011
Phase: Phase 2
Study type: Interventional

This prospective phase II trial study aims to optimize the increase in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy in treating patients with locally advanced cervical cancer.

NCT ID: NCT02562729 Completed - Clinical trials for Cervical Adenocarcinoma

Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer

Start date: September 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the feasibility of complete nerve-sparing type C1 radical hysterectomy in cervical cancer.

NCT ID: NCT02164461 Completed - Clinical trials for Cervical Adenocarcinoma

Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer

Start date: March 4, 2015
Phase: Phase 1
Study type: Interventional

To evaluate the tolerability and safety of axalimogene filolisbac 1 x 10^10 colony forming units (cfu) administered with prophylactic premedication in repeating 3-dose study cycles in women with persistent, metastatic, or recurrent squamous and non-squamous carcinoma, adenosquamous, or adenocarcinoma of the cervix. To evaluate tumor response and progression-free survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and immune-related Response Evaluation Criteria in Solid Tumors (irRECIST).

NCT ID: NCT01711515 Completed - Clinical trials for Cervical Adenocarcinoma

Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer

Start date: October 1, 2012
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of ipilimumab when given after chemoradiation therapy in treating patients with stages IB2-IIB or IIIB-IVA cervical cancer. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Monoclonal antibodies, such as ipilimumab, may find tumor cells and help carry tumor-killing substances to them. Giving ipilimumab together with chemoradiation therapy may be a better way treat cervical cancer.

NCT ID: NCT01693783 Completed - Clinical trials for Human Papillomavirus Infection

Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer

Start date: December 3, 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well ipilimumab works in treating patients with human papilloma virus (HPV)-related cervical cancer that has come back or that has spread to other areas of the body. Monoclonal antibodies, such as ipilimumab, can find tumor cells and help kill them or carry tumor-killing substances to them.

NCT ID: NCT01414608 Completed - Clinical trials for Cervical Adenocarcinoma

Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer

Start date: January 9, 2012
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies how well giving cisplatin and radiation therapy together with or without carboplatin and paclitaxel works in treating patients with cervical cancer has spread from where it started to nearby tissue or lymph nodes. Drugs used in chemotherapy, such as cisplatin, carboplatin, and paclitaxel, work in different ways to stop the growth of [cancer/tumor] cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. External radiation therapy uses high-energy x rays to kill tumor cells. Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. It is not yet known whether giving cisplatin and external and internal radiation therapy together with carboplatin and paclitaxel kills more tumor cells.

NCT ID: NCT01281852 Completed - Clinical trials for Cervical Adenocarcinoma

Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Start date: March 14, 2011
Phase: Phase 1
Study type: Interventional

This phase I clinical trial studies the side effects and best dose of veliparib when given together with paclitaxel and cisplatin and to see how well they work in treating patients with cervical cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment or that has come back. Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving more than one drug (combination chemotherapy) and giving chemotherapy together with veliparib may kill more tumor cells.

NCT ID: NCT01267253 Completed - Clinical trials for Cervical Adenocarcinoma

Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer

Start date: April 4, 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well brivanib alaninate works in treating patients with cervical cancer that has come back. Brivanib alaninate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.

NCT ID: NCT01266460 Completed - Clinical trials for Cervical Adenocarcinoma

Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer

Start date: May 23, 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well vaccine therapy works in treating patients with cervical cancer that does not go to remission despite treatment (persistent) or has come back (recurrent). Vaccines therapy may help the body build an effective immune response to kill tumor cells.